Covid-19 disease outcomes in patients receiving clozapine versus other antipsychotics
A national study in Qatar
Bibliographic Data
| ID | 15523635 |
|---|---|
| Authors | Dalia Albahari (0000-0003-1949-0102, Hamad Medical Corporation), Oraib Abdalla (Hamad Medical Corporation), Shatha Alqam (0009-0000-5418-9273, Hamad Medical Corporation), Mohammed Faisal Hamad Mohammed (Hamad Medical Corporation), Mohamed Ali Ahmed (0000-0001-8911-735X, Hamad Medical Corporation), Ovais Wadoo (0000-0001-5023-9245, Qatar University, corresponding author) |
| Year | 2025 |
| Volume | 16 |
| Pages | 1527378-1527378 |
| Publication date | 2025-05-08 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2025.1527378 |
| PMID | 40443750 |
| OpenAlex | W4410185927 |
| Language | EN |
| References cited | 1 |
Clozapine use was not associated with worse COVID-19 outcomes, supporting its relative safety during SARS-CoV-2 infection. These findings reassure clinicians regarding clozapine's continued use in treatment-resistant schizophrenia. However, the small clozapine sample size limits statistical power, warranting cautious interpretation and further research
Clozapine · Confounding · Logistic regression · Odds ratio · Psychiatry · Retrospective cohort study · Schizophrenia (object-oriented programming · Long-Term Effects of COVID-19 · Medicine · Schizophrenia research and treatment · Tryptophan and brain disorders · Internal Medicine
| Citation velocity | historical |
|---|---|
| Highly cited | No |